Not Signed In - Medarex Announces Enrollment Complete In Ipilimumab (MDX-010) Monotherapy Pivotal Registrational Trial For Metastatic Melanoma
Sat, 06 Jan 2007 08:00 AM EST
... Medarex, Inc. (Nasdaq: MEDX) today announced that enrollment has been completed in a pivotal, registrational clinical trial evaluating ipilimumab (MDX-010) as monotherapy for the second-line treatment of metastatic melanoma. [click link for full article] ...
Related Topics
- Melanoma
- Clinical Trials
- Metastatic Cancer
- non-Melanoma
- Intraocular Melanoma
- Pancreatic Cancer
- Melanoma cancer
- Melanoma of the eye
- Intraocular (Eye) Melanoma
- Eye Cancer, Intraocular Melanoma
- Placenta Previa
- Partial or complete shoulder paralysis
- Partial or complete arm paralysis
- Partial or complete loss of sensation in the fingers
- Partial or complete loss of hand movement
- Partial or complete loss of sensation in the arm (uncommon)
- Partial or complete loss of sensation in the arm, hand, or fingers
- Phobias
- Metastatic cancer to the lung
- Metastatic brain tumor
email this page
print this page
bookmark this page
feedback on this page
